Procaps Group SA (PROC) - Net Assets
Based on the latest financial reports, Procaps Group SA (PROC) has net assets worth $38.45 Million USD as of September 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($498.55 Million) and total liabilities ($460.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Procaps Group SA (PROC) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $38.45 Million |
| % of Total Assets | 7.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Procaps Group SA - Net Assets Trend (2019–2022)
This chart illustrates how Procaps Group SA's net assets have evolved over time, based on quarterly financial data. See PROC cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Procaps Group SA (2019–2022)
The table below shows the annual net assets of Procaps Group SA from 2019 to 2022. For live valuation and market cap data, see how much is Procaps Group SA worth.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-1.88 Million | +95.10% |
| 2021-12-31 | $-38.34 Million | +84.95% |
| 2020-12-31 | $-254.68 Million | -4.40% |
| 2019-12-31 | $-243.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Procaps Group SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8587900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.01 Million | % |
| Other Comprehensive Income | $11.88 Million | % |
| Other Components | $377.68 Million | % |
| Total Equity | $-941.00K | 100.00% |
Procaps Group SA Competitors by Market Cap
The table below lists competitors of Procaps Group SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Biosolution Co.Ltd
KQ:086820
|
$113.98 Million |
|
Siam Pan Group PCL
BK:SPG
|
$113.99 Million |
|
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
|
$114.00 Million |
|
Adese Gayrimenkul Yatirim AS
IS:ADESE
|
$114.01 Million |
|
Bank Panin Syariah Tbk
JK:PNBS
|
$113.72 Million |
|
We & Win Development Co Ltd
TW:2537
|
$113.63 Million |
|
InflaRx N.V
F:IF0
|
$113.59 Million |
|
Kyung Nong Corporation
KO:002100
|
$113.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Procaps Group SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -37,400,000 to -941,000, a change of 36,459,000.
- Net income of 42,540,000 contributed positively to equity growth.
- Share repurchases of 156,000 reduced equity.
- Other comprehensive income decreased equity by 3,087,000.
- Other factors decreased equity by 2,838,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $42.54 Million | +4520.72% |
| Share Repurchases | $156.00K | -16.58% |
| Other Comprehensive Income | $-3.09 Million | -328.06% |
| Other Changes | $-2.84 Million | -301.59% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Procaps Group SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-2.17 | $1.10 | x |
| 2020-12-31 | $-2.26 | $1.10 | x |
| 2021-12-31 | $-0.38 | $1.10 | x |
| 2022-12-31 | $-0.01 | $1.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Procaps Group SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.38%
- • Asset Turnover: 0.89x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -5.24% | 0.96x | 0.00x | $7.42 Million |
| 2020 | 0.00% | -3.15% | 0.92x | 0.00x | $15.10 Million |
| 2021 | 0.00% | -24.62% | 0.89x | 0.00x | $-97.12 Million |
| 2022 | 0.00% | 10.38% | 0.89x | 0.00x | $42.63 Million |
Industry Comparison
This section compares Procaps Group SA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $379,169,986
- Average return on equity (ROE) among peers: -14.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Procaps Group SA (PROC) | $38.45 Million | 0.00% | 11.96x | $113.95 Million |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $172.65 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $7.56 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $273.24 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $7.42 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $5.19 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $37.89 Million | 15.55% | 0.65x | $189.34 Million |
| ANI Pharmaceuticals Inc (ANIP) | $197.26 Million | 7.85% | 1.18x | $1.80 Billion |
About Procaps Group SA
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use… Read more